Status:
UNKNOWN
89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
Lead Sponsor:
University Medical Center Groningen
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to see whether 89Zr-bevacizumab PET scanning is feasible in relapsing multiple myeloma patients.
Detailed Description
Multiple Myeloma (MM) is a clonal B cell disorder characterised by a monoclonal plasma cell population in bone marrow, with bone pain, anaemia, hypercalcaemia, and kidney dysfunction as clinically pre...
Eligibility Criteria
Inclusion
- Patients with relapsing multiple myeloma according to international defined guidelines:
- Relapse after having achieved complete remission:
- Reappearance of paraprotein
- More than 5% plasma cells in bone marrow.
- New lytic lesions or progression of old lesions.
- New hypercalcaeamia.
- Relapse after having achieved partial remission
- Increases of paraprotein with more than 25%
- Increase of urine paraprotein with more than 25%
- Increase of plasma cells in bone marrow with 10%
- New lytic lesions or progression of old lesions
- New hypercalcaemia -
Exclusion
- Radiotherapy in the last 3 months.
- Ineligible to lay supine during the PET scan.
- Age ≤18 years.
- Pregnancy.
- Claustrophobia
- Severe kidney dysfunction; serum-creatinine ≥250 µM
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01859234
Start Date
May 1 2013
Last Update
May 21 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UMCG
Groningen, Provincie Groningen, Netherlands, 9713GZ